CA2567711C - Systeme de surveillance de caracteristiques physiologiques - Google Patents
Systeme de surveillance de caracteristiques physiologiques Download PDFInfo
- Publication number
- CA2567711C CA2567711C CA2567711A CA2567711A CA2567711C CA 2567711 C CA2567711 C CA 2567711C CA 2567711 A CA2567711 A CA 2567711A CA 2567711 A CA2567711 A CA 2567711A CA 2567711 C CA2567711 C CA 2567711C
- Authority
- CA
- Canada
- Prior art keywords
- alarm
- user
- glucose
- blood glucose
- monitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000012544 monitoring process Methods 0.000 title claims abstract description 62
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 338
- 239000008103 glucose Substances 0.000 claims abstract description 338
- 210000004369 blood Anatomy 0.000 claims abstract description 149
- 239000008280 blood Substances 0.000 claims abstract description 149
- 208000013016 Hypoglycemia Diseases 0.000 claims abstract description 63
- 238000005259 measurement Methods 0.000 claims description 116
- 230000008859 change Effects 0.000 claims description 41
- 230000003213 activating effect Effects 0.000 claims description 13
- 230000004913 activation Effects 0.000 claims description 7
- 230000001934 delay Effects 0.000 claims description 7
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 238000001802 infusion Methods 0.000 abstract description 35
- 238000000034 method Methods 0.000 abstract description 31
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 10
- 230000002618 waking effect Effects 0.000 abstract description 7
- 230000005061 slumber Effects 0.000 abstract 1
- 230000006870 function Effects 0.000 description 73
- 230000002218 hypoglycaemic effect Effects 0.000 description 66
- 230000003345 hyperglycaemic effect Effects 0.000 description 35
- 201000001421 hyperglycemia Diseases 0.000 description 35
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 32
- 238000004891 communication Methods 0.000 description 19
- 230000003466 anti-cipated effect Effects 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 102000004877 Insulin Human genes 0.000 description 16
- 108090001061 Insulin Proteins 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 229940125396 insulin Drugs 0.000 description 16
- 230000001960 triggered effect Effects 0.000 description 16
- 230000005540 biological transmission Effects 0.000 description 13
- 230000002641 glycemic effect Effects 0.000 description 13
- 238000003825 pressing Methods 0.000 description 13
- 230000000007 visual effect Effects 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 10
- 238000004364 calculation method Methods 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- 206010056997 Impaired fasting glucose Diseases 0.000 description 9
- 230000006399 behavior Effects 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000012552 review Methods 0.000 description 9
- 230000037147 athletic performance Effects 0.000 description 8
- 238000012790 confirmation Methods 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 238000009499 grossing Methods 0.000 description 8
- 230000000422 nocturnal effect Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000010409 thin film Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000008054 signal transmission Effects 0.000 description 4
- 230000004397 blinking Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 238000012806 monitoring device Methods 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 239000011295 pitch Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000001360 synchronised effect Effects 0.000 description 3
- 206010000210 abortion Diseases 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000009529 body temperature measurement Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 230000000246 remedial effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000876466 Varanus bengalensis Species 0.000 description 1
- 241000439496 Varanus dumerilii Species 0.000 description 1
- 241000857212 Varanus nebulosus Species 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013479 data entry Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- AZEVAJBARUDLQQ-BTVCFUMJSA-N formic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O AZEVAJBARUDLQQ-BTVCFUMJSA-N 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000009474 immediate action Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Abstract
L'invention concerne des appareils et des méthodes de surveillance médicale de valeurs de caractéristiques physiologiques telles que les niveaux de glycémie pour le traitement du diabète. Lesdits appareils et lesdites méthodes permettent de prévenir une quelconque conséquence négative au niveau de l'actionnement d'un moniteur et/ou d'un dispositif de perfusion suite à une désorientation qui peut se produire lors d'un réveil d'un sommeil de nuit avec un niveau de glycémie bas. L'invention concerne en outre un affichage graphique comprenant une variété d'améliorations qui permettent à l'utilisateur d'avoir facilement accès à l'historique ainsi qu'aux informations en temps réel ayant trait à la valeur de la caractéristique mesurée.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2816310A CA2816310C (fr) | 2004-06-03 | 2005-05-20 | Systeme de surveillance de caracteristiques physiologiques |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/750,080 US20050027182A1 (en) | 2001-12-27 | 2003-12-31 | System for monitoring physiological characteristics |
| US10/860,114 US7399277B2 (en) | 2001-12-27 | 2004-06-03 | System for monitoring physiological characteristics |
| US10/860,114 | 2004-06-03 | ||
| US3413404A | 2004-12-27 | 2004-12-27 | |
| PCT/US2005/019106 WO2005121785A2 (fr) | 2001-12-27 | 2005-05-20 | Systeme de surveillance de caracteristiques physiologiques |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2816310A Division CA2816310C (fr) | 2004-06-03 | 2005-05-20 | Systeme de surveillance de caracteristiques physiologiques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2567711A1 CA2567711A1 (fr) | 2005-12-22 |
| CA2567711C true CA2567711C (fr) | 2013-07-30 |
Family
ID=37682491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2567711A Active CA2567711C (fr) | 2003-12-31 | 2005-05-20 | Systeme de surveillance de caracteristiques physiologiques |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2567711C (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108281200A (zh) * | 2016-12-30 | 2018-07-13 | 上海移宇科技股份有限公司 | 一种在动态血糖监测系统中调整算法的方法及应用该方法的动态血糖监测系统 |
-
2005
- 2005-05-20 CA CA2567711A patent/CA2567711C/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2567711A1 (fr) | 2005-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2816310C (fr) | Systeme de surveillance de caracteristiques physiologiques | |
| US7399277B2 (en) | System for monitoring physiological characteristics | |
| US20080255438A1 (en) | System for monitoring physiological characteristics | |
| CA2550855C (fr) | Systeme permettant de controler des caracteristiques physiologiques | |
| US7022072B2 (en) | System for monitoring physiological characteristics | |
| US10080529B2 (en) | System for monitoring physiological characteristics | |
| US10448834B2 (en) | Smart messages and alerts for an infusion delivery and management system | |
| EP2862586B1 (fr) | Unité de commande pour unités de pompe à perfusion comprenant une unité d'intervention contrôlée | |
| CA2567711C (fr) | Systeme de surveillance de caracteristiques physiologiques |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |